March 16, 2021 -- Tevogen Bio has partnered with contract development and manufacturing organization (CDMO) BioCentriq to support clinical manufacturing of Tevogen's investigational COVID-19 cell therapy.
Under the partnership, both companies will collaborate at BioCentriq's good manufacturing practice (GMP) facilities in New Jersey to produce Tevogen's proprietary COVID-19-targeted T cells. The goal is to achieve large-scale manufacturing of clinical-grade, allogeneic T-cell therapy.
The U.S. Food and Drug Administration (FDA) is currently reviewing Tevogen's investigational new drug (IND) application for the antigen-specific T-cell therapy. In upcoming trials, Tevogen will study its COVID-19-specific CD8+ T cells, TVGN-489, for the drug's safety and ability to recognize and eliminate COVID-19-infected cells.
Financial details of the partnership were not disclosed.